Name | Type | Posted | Actions |
|---|---|---|---|
JOFOC CAPS 503A and 503B outsoursing 04.2026.docx | DOCX | May 20, 2026 |
NOI to Sole Source to Central Admixture Services, Inc.
Contact and place of performance
Huda Malik
Bethesda, MD 20892
USA
The purpose of this acquisition is to contract with a source for select non-patient-specific sterile compounded products and patient specific parenteral nutrition and renal replacement therapy that meet the quality expectations to provide to National Institutes of Health Clinical Center (NIH CC) patients on an ongoing basis. • Product...
View moreThe proposed vendor, CAPS Inc., is the Original Manufacturer and has not designated other distributors for compounded products in the U.S.
This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.
Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Huda Malik, Contract Specialist via email to [email protected] by May 26, 2026 by 3 pm EST.
The National Institutes of Health (NIH) intends to award a firm-fixed-price, sole-source contract to Central Admixture Pharmacy Services, Inc. (CAPS, Inc.) for the procurement of select non-patient-specific sterile compounded products. This acquisition also covers patient-specific parenteral nutrition and renal replacement therapy required for ongoing patient care at the NIH Clinical Center in Bethesda, Maryland. The proposed vendor is the original manufacturer and does not utilize other distributors for these compounded products in the United States.
This requirement is identified under solicitation number NOI-OD-26-000037 and is classified under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6515 Medical and Surgical Instruments, Equipment, and Supplies. There is no set-aside designated for this action. The NIH is conducting this procurement through simplified acquisition procedures, citing that only one source is reasonably available to meet the quality expectations and technical requirements of the clinical center.
The proposed contract features a one-year performance period. While this notice of intent is not a request for quotations and a formal solicitation will not be issued, interested parties may submit comments regarding the requirement to the National Institutes of Health OLAO. Responses are due to the point of contact, Huda Malik, by 3:00 PM EST on May 26, 2026. One attachment, a justification for other than full and open competition, was included with the notice published on May 20, 2026.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.